Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

India's Gland Pharma to make up to 252 million Sputnik V vaccine doses

03/16/2021 | 06:05am EDT
FILE PHOTO: A Palestinian health worker displays a vial of Russia's Sputnik V vaccine as he prepares to vaccinate Matthias Schmale, UNRWA's Gaza director, against the coronavirus disease (COVID-19), in Gaza City

BENGALURU (Reuters) - Gland Pharma Ltd said on Tuesday it had struck a deal with the Russian Direct Investment Fund (RDIF) to make up to 252 million doses of the Sputnik V COVID-19 vaccine, bringing India's total production of the shot to at least 352 million.

Shares of Gland Pharma, which is backed by China-based Shanghai Fosun Pharmaceutical Group Co Ltd, surged as much as 9.5% to hit a record high of 2,783.85 rupees.

India's Hetero already has a deal in place to produce over 100 million doses of the vaccine, which has proven to be 91.6% effective against COVID-19.

Sputnik V, developed by Moscow's Gamaleya Institute, has been approved in 22 countries, with the RDIF signing supply deals with over 13 countries.

Indian drugmaker Dr.Reddy's Laboratories Ltd has also been holding small clinical studies of Sputnik V domestically. It had sought emergency use approval for the vaccine last month, but India's drug regulator had asked for more data.

Production is expected to begin in the third quarter at its facilities in Hyderabad, with deliveries estimated in the final quarter of the year, Gland Pharma said in a statement. It did not specify which countries it would supply the doses to.

Gland Pharma also said it would explore more deals for the vaccine.

India, the world's biggest vaccine maker, has so far given emergency use approval to AstraZeneca Plc's shot and a homegrown vaccine made by Bharat Biotech. It has donated or sold vaccines to more than three dozen countries, while significantly ramping up its own inoculation program this month.

European Union (EU) governments are considering launching talks with Sputnik V developers as the EU tries to get its vaccination program back on track, EU diplomatic and official sources have told Reuters.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Devika Syamnath and Anil D'Silva)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.11% 8268 Delayed Quote.12.89%
DR. REDDY'S LABORATORIES LIMITED 0.89% 4712.7 End-of-day quote.-9.44%
GLAND PHARMA LIMITED -1.28% 3948.45 End-of-day quote.68.72%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 9.54% 81.88 End-of-day quote.51.66%
All news about ASTRAZENECA PLC
10:43aCORONAVIRUS : Kenya has Received an Additional 410,000 Doses of AstraZeneca The ..
07/30ASTRAZENECA : H1 2021 results
07/30ASTRAZENECA : NHS - Presidential visit strengthens healthcare partnership with K..
07/30ASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine..
07/30ASTRAZENECA : Shortages Hamper Ohangwena Vaccination Drive
07/30ASTRAZENECA : Receives a Buy rating from Credit Suisse
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
07/29AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
07/29ASTRAZENECA : to seek US approval of COVID vaccine in 2nd half
More news
Financials (USD)
Sales 2021 34 636 M - -
Net income 2021 5 207 M - -
Net Debt 2021 26 467 M - -
P/E ratio 2021 30,4x
Yield 2021 2,45%
Capitalization 178 B 178 B -
EV / Sales 2021 5,90x
EV / Sales 2022 4,74x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 114,91 $
Average target price 133,75 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.89%178 110
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343